April 20 (Reuters) - Atara Biotherapeutics Inc-
* Atara Bio announces positive interim results from ongoing phase 1 trial of the autologous version of ata188 in patients with primary and secondary progressive multiple sclerosis (ms) at the american academy of neurology (aan) annual meeting 2017
* Atara Biotherapeutics Inc - look forward to further development of autologous ata188 for patients with ms
* Atara Biotherapeutics Inc - expected initiation of both phase 1 allogeneic ata188 trial as well as our phase 3 trials of ata129 in second half of year.
* Atara Biotherapeutics Inc - no patient in trial experienced progression of disability; there was no worsening in edss Source text for Eikon: Further company coverage: